1[1]Erslev AJ,Besarab A.Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure[J].Kidney Int,1997,51 (2):622-630.
2[2]Vaziri ND,Kaupke CJ,Barton CH.Plasma concentration and urinary excretion of erythropoiet in adult nephrotic syndrome[J].Am J Med,1992,92(1):35-40.
3[3]Eschbach JW,Egrie JC,Downing MR,et al.Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.Results of combined phase Ⅰ and Ⅱ clinical trials[J].N Eng J Med,1987,316(1):73-78.
4[4]Gansevoort RT,Vaziri ND,de Jong PE.Treatment of anemia of nephrotic syndrome with recombinant erythropoietin[J].Am J Kidney Dis,1996,28(4):274-277.
5[5]Bucker FS,Eschbach JW,Haley NR,et al.Hypertension following erythropoietin therapy in anemia hemodialysis patients[J].Am J Hypertens,1990,3 (5):947-955.
6[6]Raine AE,Roger SD.Effects of erythropoietin on blood pressure[J].Am J Kidney Dis,1991,18(1):76-83.
7[7]Raine AE.Hypertension,blood viscosity,and cardiovascular morbidity in renal failure:implications of erythropoietin therapy[J].Lancet,1988,1(8577):97-100.
9[9]Vaziri ND,Zhou XJ,Naqvi F,et al.Role of nitricoxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure[J].Am J Physiol,1996,271 (3):El 13-E122.
10[10]Kaupke CJ,Kim S,Vaziri ND.Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy[J].J Am Soc Nephrol,1994,4(6):1874-1878.
